Once-daily oral brepocitinib 30 mg shows improvement in measures of skin and muscle disease in patients with dermatomyositis, compared with placebo, according to findings from a phase 3 study.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/brepocitinib-shows-positive-results-phase-3-dermatomyositis-2025a1000p1n?src=rss
Author :
Publish date : 2025-09-19 18:53:00
Copyright for syndicated content belongs to the linked Source.
